医学临床研究
   Jul. 14, 2025    Home  |  About Journal  |  Editorial Board  |  Instruction  |  Subscribe  |  Advertisement  |  Messages Board  |  Contact Us  |  中文
JOURNAL OF CLINICAL RESEARCH  2022, Vol. 39 Issue (7): 1072-1074    DOI: 10.3969/j.issn.1671-7171.2022.07.031
OriginalArticles Current Issue | Archive | Adv Search |
Clinical Effect of Linezolid Combined with Cefotaxime Sodium in the Treatment of Neonatal Purulent Meningitis and its Effect on the Levels of Nerve Injury Factors,IL-12 and SAA in Children
CHEN Wei, DONG Zi-ran, WANG Qin-qin
Shangluo Central Hospital,Shangluo Shaanxi 726000
Download: PDF (1128 KB)   HTML (1 KB) 
Export: BibTeX | EndNote (RIS)      
Abstract  【Objective】 To investigate the clinical effect of Linezolid combined with Cefotaxime sodium in the treatment of neonatal purulent meningitis and its effect on the levels of nerve injury factor, interleukin-12 (IL-12) and serum amyloid A (SAA). 【Methods】 The clinical data of 86 newborns with suppurative meningitis treated in our hospital were retrospectively analyzed. According to the different methods of medication, they were divided into observation group and control group, with 43 cases in each group. The control group was treated with cefotaxime sodium, and the observation group was treated with linezolid on the basis of the control group, both of which were treated for one week. The curative effects of the two groups were compared, including the levels of nerve injury factor [neuron specific enolase (NSE), S100β Protein], IL-12, SAA, cerebrospinal fluid protein content, total cell count, glucose level before and 1 week after treatment, and the incidence of adverse reactions was counted. 【Results】After one week of treatment, the total effective rate in the observation group was 95.35% (41/43), which was higher than 76.74% (33/43) in the control group, and the difference was statistically significant (P<0.05); The protein levels of serum IL-12,SAA, NSE and S100β in both groups were lower than those before treatmentin, and the observation group was lower than the control group (P<0.05) ; The protein content and total number of cells in cerebrospinal fluid of the two groups were lower than that before treatment, and the glucose level was higher than that before treatment. The difference between the observation group and the control group was statistically significant (P<0.05). The incidence of adverse reactions in the observation group was 13.95% (6/43), lower than 6.98% (3/43) in the control group, but the difference was not statistically significant(χ2=0.49,P=0.48). 【Conclusion】Linezolid combined with Cefotaxime sodium is effective in the treatment of neonatal purulent meningitis, which can reduce inflammatory reaction, inhibit nerve injury, and has good safety.
Key wordsMeningitis      Infant, Newborn      Interleukin-12      Serum Amyloid A Protein     
Received: 13 September 2021     
PACS:  R515.2  
Service
E-mail this article
Add to my bookshelf
Add to citation manager
E-mail Alert
RSS
Articles by authors
CHEN Wei
DONG Zi-ran
WANG Qin-qin
Cite this article:   
CHEN Wei,DONG Zi-ran,WANG Qin-qin. Clinical Effect of Linezolid Combined with Cefotaxime Sodium in the Treatment of Neonatal Purulent Meningitis and its Effect on the Levels of Nerve Injury Factors,IL-12 and SAA in Children[J]. JOURNAL OF CLINICAL RESEARCH, 2022, 39(7): 1072-1074.
URL:  
http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2022.07.031     OR     http://journal07.magtech.org.cn/yxlcyj/EN/Y2022/V39/I7/1072
Copyright © Editorial Board of JOURNAL OF CLINICAL RESEARCH
Supported by:Beijing Magtech